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Abstract
Platelets are small, anucleate cells that travel as resting discoid fragments in the circula-
tion. Their average circulating life span is 8–9 days, and their formation is an elegant 
and finely orchestrated series of cellular processes known as megakaryocytopoiesis 
and thrombopoiesis. This involves the commitment of haematopoietic stem cells, pro-
liferation, terminal differentiation of megakaryocytic progenitors and maturation of 
megakaryocytes to produce functional platelets. This complex process occurs in spe-
cialised endosteal and vascular niches in the bone marrow where megakaryocytes form 
proplatelet projections, releasing platelets into the circulation. Upon contact with an 
injured blood vessel, they prevent blood loss through processes of adhesion, activation 
and aggregation. Platelets play a central role in cardiovascular disease (CVD), both in 
the development of atherosclerosis and as the cellular mediator in the development 
of thrombosis. Platelets have diverse roles not limited to thrombosis/haemostasis, also 
being involved in many vascular inflammatory conditions. Depending on the physio-
logical context, platelet functions may be protective or contribute to adverse thrombotic 
and inflammatory outcomes. In this chapter, we will discuss platelets in context of their 
formation and function. Because of their multifaceted role in maintaining physiological 
homeostasis, current and development of platelet function testing platforms will be 
discussed.
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1. Introduction
Efforts in coping with the socio-economic and health burden of CVD require further under-
standing of its aetiology and the risk factors behind it in order to develop cost-effective preven-
tive strategies (primordial, primary, secondary and tertiary) to prevent and manage it. CVD 
risk factors can be classed as modifiable or non-modifiable. Modifiable risk factors included 
smoking, diabetes, unhealthy diet, cholesterol, physical inactivity (sedentary lifestyle and low 
cardiorespiratory fitness), overweight and obesity. Risk factors for CVD track from childhood 
into adulthood and are strong predictors of subclinical disease in early adulthood [1]. Up to 
80% of CVD may be prevented if modifiable risk factors are evaded [2].
The main functions of blood are to supply oxygen and nutrients to tissues and cells, removal 
of waste, and regulation of pH and body temperature [3]. An average adult has approximately 
five litres of blood, accounting for about 7% of their body weight. Blood is composed of approxi-
mately 55% plasma; a pale yellow fluid mainly consisting of water, proteins, sugars and fat 
particles, and 45% blood cells. Blood cells include erythrocytes, leukocytes and platelets. Each of 
these cells are derived from a haematopoietic stem cell (HSC), which reside in the bone marrow 
and sit at the peak of a developmental hierarchy, with unique ability to self-renew and give rise 
to cells of all of the blood lineages [4]. In adults, nearly a trillion new blood cells are produced 
daily to sustain steady state in circulation [5]. In the classic model of haematopoiesis (the pro-
duction of blood cells), an important bifurcation occurs between the lymphoid and myeloid 
branches, which then further divide into a number of progenitor cells (Figure 1). While the 
main function of red blood cells (RBCs) and white blood cells (WBCs) is oxygen transport and 
defence, respectively, this chapter will focus on platelets, the final product of one of the myeloid 
Figure 1. Pictorial representation of megakaryocytopoiesis and thrombopoiesis, and the potential for exposome and 
epigenome modulation of platelet phenotype and function during this dynamic cellular differentiation process.
Homeostasis - An Integrated Vision72
cell lines. In addition, the principle hypothesis and paradigm discussed will be that the modifi-
able lifestyle factors of physical activity and inactivity can impact on the processes of both mega-
karyocytopoiesis and thrombopoiesis, via epigenetic mechanisms. We propose that physical activity/
inactivity can modulate and program platelet phenotype and therefore function. Through recent 
studies, including our own (manuscripts in preparation), it is becoming increasingly evident 
that lifestyle factors such as physical (in)-activity and high BMI do impact on platelet function. 
Thus, various research studies have collectively demonstrated that platelets are indeed reflec-
tive of physiological and lifestyle changes, making them sensitive biomarkers of human health. 
Platelets represent a tangible link to physiological and pathological changes within the body. 
Future investigations will undoubtedly contribute to a greater mechanistic understanding of the 
relationship between cardiovascular health, lifestyle factors and platelet biology.
2. Platelets
2.1. Platelet production
Gulio Bizzozero first described platelets as ‘spherules piastrine’ (little plates) as small cell 
fragments that clumped together at an injured blood vessel site. He also showed that these 
blood elements did not have a nucleus [6]. Circulating anucleate platelets are now described 
as dynamic specialised cells, formed in an elaborate style from their precursor cell, the mega-
karyocyte. Normal platelet counts ranges between 150 and 450 × 103 per microliter of blood, 
constituting the second most abundant cell type in blood after red blood cells. The average 
adult produces 1011 platelets per day to preserve this count. Platelets travel as resting (qui-
escent) discoid fragments in the circulation, while an elaborate internal cytoskeleton allows 
shape changes to occur upon contact with an injured blood vessel.
The size of a mature platelet is approximately 2–4 μm, making them the smallest cells in circu-
lation, while their average thickness is 0.5 μm [7] and their volume about 7 μm3. Their small size 
facilitates in their role as ‘guardians of the vasculature’, as under laminar flow environments, 
platelets are pushed to the periphery by larger white and red blood cells. Consequently, they 
remain in close proximity to the blood vessel wall where they can quickly respond to any 
vascular damage [8]. This enables platelets to perform their main physiological function to 
prevent blood loss in primary haemostasis by the formation of a ‘platelet plug’ [9].
Platelets are formed and released into the bloodstream from megakaryocytes (MKs), which 
reside in the bone marrow [10, 11]. Their production is arguably the most elegant and distinct 
developmental process in eukaryotes [12]. While accounting for only 0.01% of nucleated bone 
marrow cells, MKs are also the largest cells, measuring between 50 and 100 μm [13]. Both MK 
and platelet production, termed megakaryocytopoiesis and thrombopoiesis, are regulated by 
multiple cytokines, with thrombopoietin (TPO), a hormone produced by the liver and kid-
neys, being the key regulator. In response to TPO, HSCs differentiate into MKs by differential 
expression of various transcription factors. This maturation is characterised by a growth in 
MK size and DNA ploidy levels (endomitosis), enabling the accumulation of RNA, protein 
and organelles in the MK for packaging into platelets. MKs then migrate to the sinusoidal 
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blood vessels in the vascular niche where numerous long processes called pro-platelets are 
formed. MKs can extend as many as 20 pro-platelets which branch repeatedly over time. 
Platelets form at the tips of pro-platelets, receiving organelles, genetic material and granule 
contents that are transported from the MK cell body. The final point of platelet production 
occurs in circulation whereby anucleate fragments of pro-platelets bud into pre-platelets 
[14] and barbell-shaped platelets [15] that are subsequently converted into single platelets 
in a microtubule-driven process [16] aided by the shear forces within the bloodstream [11]. 
Platelets then have an average lifespan of 8–10 days, after which they are cleared via phago-
cytic cells such as macrophages in the spleen. Apoptosis (programmed cell death) is also well 
recognised in the anucleate platelet [17]. The constant number of platelets in circulation is a 
consequence of a homeostatic balance between their production and destruction/clearance.
2.2. Platelet structure
2.2.1. Internal
Platelets are unique in their structural composition and, while anucleate, contain a large 
variety of cellular organelles, granules and mitochondria. Granules are generally secretory 
vesicles that release their contents either to the platelet surface or to extracellular fluid by 
endocytosis. Over 300 proteins from platelet granules have been identified in the platelet 
releasate following activation [18, 19]. Three types of platelet granules have been identified: 
α-granules, dense granules, and lysosomal granules all of which derive their cargo from MKs. 
α-granules are the largest and most numerous (50–80 per platelet) encompassing roughly 
10% of the platelet volume [20]. They harbour a vast assortment of proteins important for 
primary haemostasis including integrins (αIIbβ3) immunoglobulin family receptors (e.g. 
GPVI, PECAM), leucine-rich repeat family receptors (e.g., GPIb-IX-V complex), tetraspanins 
(e.g., CD9) and other adhesive proteins such as von Willebrand Factor (vWF), fibrinogen, 
and coagulation factors (Factors V, XI) that participate in secondary haemostasis. While it 
was previously assumed that platelet α-granules were homogenous populations, [21] sug-
gested that platelets have distinct subpopulations of alpha granules which differentially 
release their cargo in a context-dependent manner. Dense granules are smaller in size and 
number (3–8 per platelet) storing high concentrations of non-protein molecules that potenti-
ate platelet activation such as adenosine diphosphate (ADP), adenosine triphosphate (ATP), 
calcium, histamine, polyphosphate and serotonin [22, 23]. Lysosomal granules are sparse 
and harbour enzymes such as acid hydrolases and proteases). They function in the digestion 
of cytosolic components. Secretion of the lysosomal content has key extracellular functions 
including receptor cleavage, fibrinolysis and degradation of extracellular matrix (ECM) [24]. 
A recent report has described a possible new type of secretory granule termed a T-granule, 
after their tubular morphology [11]. These novel electron-dense granules have been proposed 
to function in toll-like receptor (TLR) organisation and signalling. Platelet granule deficiencies 
or defects such as the Grey Platelet Syndrome (α-granule deficiency) or Hermansky-Pudlak 
Syndrome (dense granule deficiency) can cause mild to severe bleeding disorders [25].
Platelets contain functional mitochondria, which despite being few in number, have higher 
rates of ATP turnover than resting mammalian muscle, suggesting they are very metabolically 
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active [26]. The traditional role of mitochondria in the platelet is to the supply of energy in 
the form of ATP for primary platelet functions. However, novel functions for mitochondria 
continue to emerge. Dual activation of platelets with collagen and thrombin results in a sub-
type of platelets known as collagen and thrombin activated (COAT) platelets. COAT platelets 
display striking alterations in function and structure to typical “activated platelets” by exhib-
iting a myriad of features such as phosphatidylserine exposure due to cytoskeletal reorgan-
isation, high microparticle release, and increased levels of fibrinogen on the platelet surface 
[27]. Mitochondrial membrane potential (ΔΨ
m
) is reduced in (COAT) platelets and decreases 
in parallel with elevated mitochondrial ROS levels that are necessary for facilitating platelet 
PS exposure upon activation [28]. Mitochondria are involved in the process of platelet apop-
tosis [29] and can be released from platelets as potential inflammatory mediators [30].
2.2.2. Surface receptors
Platelets express a wide variety of receptors on their membrane, which are fundamental to 
platelet function and downstream signalling [9]. Major receptors include integrins, leucine-
rich repeat receptors (Glycoprotein GPIb/IX/V, Toll-like receptors), C-type lectin receptors 
(P-Selectin, CLEC-2), tyrosine kinase receptors (Ephrins and Eph kinases), proteins belonging 
to the immunoglobulin superfamily (GPVI, FcγRIIA) and other receptors shared with vascu-
lar cells (TNF receptor type, CD63, CD36, PSGL-1).
Integrins are type I transmembrane cell adhesion receptors [31] consisting of a short intracel-
lular and larger extracellular domain. All integrins contain an α subunit and a β subunit, 
capable of bi-directional signalling. During signal transduction, they transmit information 
concerning the chemical and mechanical status of the ECM to the cell [32, 33]. Platelets 
express five integrin receptors—each with affinity for specific ligands; αIIbβ3 (fibrinogen), 
α2β1(collagen), α5β1(fibronectin), αVβ3 (vitronectin) and α6β1 (laminin), all of which share 
related signal transduction processes [34]. On the cytoplasmic face of the plasma membrane, 
integrins regulate cytoskeletal dynamics and signalling complexes. On the extracellular side, 
integrins bind with high affinity to either ECM ligands or counter receptors on adjacent cell 
surfaces [35]. αIIbβ3 is the most abundant platelet integrin, with copy numbers of ~50,000 
per platelet, and is present in both alpha granules and the platelet surface. Platelets express a 
number of G-protein coupled receptors (GPCRs) which constitute a large family of receptors 
that can identify molecules outside the cell and initiate signal transduction pathways and 
ultimately cell function. The main GPCRs present on platelets include thrombin receptors 





which approximately 150 P2Y
1
 receptors are present on the platelet [36], thromboxane recep-
tors (TPα and TPβ) and glycoprotein receptors [37].
2.3. Platelet function
2.3.1.  Platelet function in primary haemostasis
Haemostasis can be subdivided into primary haemostasis, secondary haemostasis and fibri-
nolysis (Figure 2) [38]. Platelets prevent blood loss in primary haemostasis, the physiological 
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Figure 2. (A) Diagram showing key platelet membrane receptors involved in platelet function in haemostasis and 
thrombosis. (B) Distinct phases of platelet function in primary haemostasis: Initial platelet tethering and adhesion at 
a site of vascular damage, firm adhesion and shape change, activation, granule secretion and further recruitment of 
platelets leading to platelet aggregation. (C) Secondary haemostasis: Formation, deposition and cross-linking of insoluble 
fibrin, generated by the coagulation cascade, to stabilise the primary platelet plug. (D) Image of platelet aggregates 
(fluorescently-labelled, green) on collagen fibrils following in vitro blood flow at arterial shear (1800 s−1) using a parallel-
plate blood perfusion chamber (unpublished data—Gerardene Meade-Murphy).
process which halts bleeding at an injured blood vessel, while maintaining normal blood 
flow elsewhere in circulation, by the formation of a ‘platelet plug’ [11]. Secondary haemosta-
sis refers to the deposition of insoluble fibrin that is generated by the coagulation cascade. 
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Finally, fibrinolysis results in the breakdown of blood clots during wound healing involving 
the interplay of a number of enzymes [38]. A healthy endothelium provides a non-adhesive 
surface for platelets. However, in areas of vascular injury, the sub-endothelium is exposed 
and platelets may adhere quickly to different extracellular matrix components, and then form 
a platelet plug. This process is achieved through three distinct processes—platelet adhesion, 
platelet activation and secretion, and platelet aggregation [39].
2.3.2. Platelet adhesion
Platelet adhesion entails a collaborative effort of various platelet receptors, fundamentally lead-
ing to platelet activation and aggregation. ECM elements that platelets adhere to include pro-
teins such as collagen, vWF, fibronectin, laminin and fibrinogen among others [40, 41]. Among 
these subendothelial substrates, the thrombogenic fibrillar collagens type I and III are the most 
powerful intermediaries of platelet adhesion due to their robust activating potential and affin-
ity for vWF [42]. Following vascular damage, initial platelet ‘tethering’ is mediated by the inter-
action between the A1 domain of vWF deposited in the subendothelial matrix of the damaged 
vessel wall, and the GPIbα in the platelet receptor GPIb-IX-V. This interaction is particularly 
important at high shear rates supporting platelet translocation (i.e. decelerating platelets and 
keeping them in close contact with the endothelium) over the subendothelium, but not stable 
adhesion [43]. This interaction allows engagement of other platelet receptors. vWF/GPIb-IX 
interface also induces platelet activation signalling events, resulting in integrin activation [44].
Following platelet tethering, platelet collagen receptors, GPVI and α2β1 interact with exposed 
collagen and promote platelet adhesion and activation. GPVI is non-covalently coupled to the Fc 
Receptor chain (FcRγ) [45, 46] and has been acknowledged as the major signalling receptor for 
collagen. FcRγ has an immunoreceptor tyrosine-based activation motif (ITAM) on its cytoplasmic 
sphere. After collagen binding to GPVI, the ITAM motif on the GPVI/FcRγ complex is phosphory-
lated, resulting in activation of the Syk kinase pathways that phosphorylate downstream targets, 
ultimately resulting in increased cytosolic Ca2+ and subsequent platelet shape change, granule secre-
tion and integrin activation. GPVI has a low affinity for collagen, rendering it unable to mediate 
stable adhesion alone. The α2β1 integrin then maintains stable adhesion to collagen. α2β1 stimulates 
downstream steps indirectly by reinforcing GPVI-collagen interactions [41, 47] and by direct signal-
ling leading to activation of αIIbβ3. Platelet Ca2+ signalling is markedly dissimilar between GPVI 
and α2β1 suggesting that the alliance regarding GPVI and α2β1 supports optimal platelet adhesion.
The final step of platelet adhesion occurs via binding of platelets to other ECM components 
such as fibronectin, laminin and immobilised vWF. Platelets bind to fibronectin via the α5β1 
receptor and αIIbβ3, whilst adhesion to laminin is mediated by their α6β1 receptor. Stable 
binding of platelets elicits activation pathways involving tyrosine kinases and signal trans-
duction GPCR receptor signalling, cumulatively resulting in elevated cytosolic Ca2+ levels, 
cytoskeletal reorganisation and integrin activation.
2.3.3. Platelet activation and secretion
Once platelet adhesion has occurred at the site of vessel wall damage, platelet activation 
needs to be maintained for haemostasis to continue. Essential for the amplification of platelet 
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activation is the production and release of soluble agonists at the site of damage [26], which 
act in an autocrine and paracrine manner to amplify platelet activation and recruit further 
circulating platelets. These agonists consist of TxA
2
, ADP, epinephrine and thrombin. ADP 





on the platelet surface [48]. ADP is also released from red blood cells at the site of vascular 
damage [37]. Binding of ADP initiates a full complement of activation events such as elevation 
of intracellular platelet Ca2+, TxA
2
 synthesis, protein phosphorylation, shape change, granule 
release, and most importantly, activation of αIIbβ3 [49]. P2Y
12
 is also the target of a class of 
antiplatelet drugs called thienopyridines (ticlopidine, clopidogrel, prasugrel), widely used in 
the prevention of vascular events in patients with CVD.
TxA
2
 is a potent platelet agonist synthesised from arachidonic acid through the COX path-
way and TxA
2
 synthase enzymes. It subsequently binds to TPα and TPβ receptors that differ 
in their cytoplasmic tails, causing vasoconstriction, shape change, protein phosphorylation, 
secretion and platelet aggregation [50, 51]. Indeed, high levels of TxA
2
 have been implicated 
in CVD, whilst inhibition of TxA
2
 synthesis through aspirin-mediated COX inhibition is a 
major anti-platelet target.
The agonist thrombin rapidly accumulates at sites of vascular damage and has major func-
tions in promoting and stabilising thrombus formation. Platelets release factors that sup-
port the activation of prothrombin, which after a complex series of sequential events in the 
coagulation cascade, results in the generation of thrombin [52]. The increase in cytosolic Ca2+ 
after platelet activation results in platelet phosphatidylserine (PS) exposure on the activated 
platelet membrane providing a procoagulant surface for thrombin to interact with its PAR1 
and PAR4 (G protein-coupled) receptors.
Uniquely, thrombin activates its PAR-receptors by cleaving an N-terminal part at a consen-
sus site. Cleavage exposes a new binding site that acts as a ligand to activate the receptor. 
Thrombin is the most powerful platelet activator, initiating an entire complement of platelet 
responses (shape change, granule secretion, TxA
2
 synthesis, aggregation etc.) [53]. Thrombin 
can activate platelets at extremely low concentrations and within seconds, increases cytosolic 
level of Ca2+, eliciting downstream signalling events. Unlike ADP, TxA
2
 or thrombin, the cat-
echolamine epinephrine is a weak agonist unable to cause shape change alone. However, it 
works collectively with the other agonists increasing their potential to activate. Epinephrine’s 




The ultimate step in primary haemostasis is platelet aggregation, caused by crosslinking of 
αIIbβ3 on adjacent platelets by fibrinogen (Figure 2). While platelet aggregation is a complex 
process involving different receptors (αIIbβ3 and GPIbα) and ligands (fibrinogen, fibronec-
tin, and vWF), the main process involves the integrin αIIbβ3. On resting platelets, integrin 
αIIbβ3 has a low affinity for its ligands fibrinogen and vWF, which dramatically increases 
upon platelet activation. Binding of the main agonists to their respective receptors induce 
intracellular signals that disrupt the complex between the cytoplasmic tails of αIIbβ3. This 
ultimately leads to a conformational change in its extracellular globular head domains from a 
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low affinity resting state to a high affinity activated state in order to bind extracellular ligands 
such as fibrinogen and vWF. Irreversible activation of αIIbβ3 is a prerequisite for the develop-
ment of irreversible platelet aggregates. Due to the symmetrical nature of fibrinogen, platelets 
can be ‘bridged’ and platelet aggregates are formed [40]. While αIIbβ3 is the major player 
in platelet aggregation, couplings between other platelet receptors and their ligands could 
be incorporated in aggregation. Some of these comprise CD40 ligand [55] interaction with 
αIIbβ3, the vWF-GPIb complex [56], and an involvement of fibronectin in stabilising platelet 
aggregation [57, 58]. Cadherin-6 was recently acknowledged as a new counter-receptor for 
αIIbβ3, involved in platelet aggregation [59].
Bi-directional ‘inside out’ and ‘outside in’ signals are transferred by both integrin subunits, 
mediating receptor conformation and platelet function [44]. After platelet stimulation with 
ADP, the signal from the ADP receptors is conducted to the intracellular domain of the cyto-
plasmic tail of αIIbβ3 and subsequently transmitted through a series of events to the extracel-
lular domain (inside-out) causing a conformational change in the extracellular domain that 
binds to its ligand. Inside-out signalling necessitates binding of talin and kindlins to the cyto-
plasmic domain of β3. After ligand binding, a signal is sent to the cell (outside-in) to control 
platelet function such as filopodia and lamellipodia extension to dull platelet spreading [34, 
44]. Furthermore, αIIbβ3 outside-in signals can also act as a break to curb excessive platelet 
activation by activated SHIP-1 [60].
2.3.5. Bio rheological factors in platelet aggregation
A significant factor influencing platelet aggregation is the distinct shear environment experi-
enced within the vascular system. Platelets are subjected to fluctuating haemodynamic condi-
tions in vivo such as shear stress and shear rate. The latter refers to the rate of increase of blood 
flow velocity, whereas the former denotes the force per unit area on the vessel wall [61]. Shear 
rates experienced by platelets range from slow flow in veins (shear rate 10 s−1 to 500 s−1) to 
small arteries (approx. 2000 s−1) to diseased or pathological arteries, where extremely high 
shear rates (up to 40,000) have been described [61, 62]. Increasing shear rate activates platelets 
itself. At low shear rates (<1000 s−1), platelet aggregation is primarily facilitated by αIIbβ3-
fibrinogen interactions. At shear rates typically over 5000 s−1 (but between 1000 and 10,000), 
a two-step sequential process occurs. The first depends on the adhesive properties of GP1bα 
and αIIbβ3 and is facilitated by the formation of reversible platelet aggregates. The second 
relies on the generation of platelet agonists and involves the irreversible activation of αIIbβ3 
to form stable aggregates [63]. Accordingly, both fibrinogen and vWF, and receptors GPIbα 
and αIIbβ3, have distinctive but complementary roles in platelet aggregation subject to the 
haemodynamic environment.
2.3.6. Signal transduction during platelet function
The role of platelets in haemostasis is reliant on the equilibrium between activatory and 
inhibitory signals [64]. Inhibitory signals from the vasculature prevent platelet activation in 
healthy vessels. Activatory signals present at an injured blood vessel initiate platelet activa-
tion, and are managed by endogenous negative signalling regulators. Negative regulators 
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and pathways include the ITIM containing receptors that are postulated to reduce activation 
of PLC, PI3K and integrin αIIbβ3 [64]. The Wnt-β-catenin pathway has recently gained atten-
tion as negative regulator of platelet function [65, 66]. Wnt3a is one of these glycoproteins, 
which is secreted from activated platelets. It has been suggested to activate the canonical 
Wnt-β-catenin pathway as constituents of this pathway have been identified in platelets. The 
regulation of small GTPases such as Rap1, Rac1, RhoA and Cdc42 has been suggested as play-
ers in this inhibition of platelet function [65]. These pathways are less well characterised than 
the classical activation pathways [67]. The primary platelet inhibiting signals produced by 
healthy ECs are nitric oxide and prostacyclin. Both NO and prostacyclin relax blood vessels 
and prevent platelet activation [68]. NO is synthesised from several cells including plate-
lets, ECs and RBCs and plays vital roles in maintaining platelets in a resting state [69–71]. 
Prostacyclin (PGI
2
) is a physiological anti-aggregating agent produced constitutively by ECs 
as a result of arachidonic acid metabolism by cyclooxygenase (COX) enzymes.
Following endothelial damage, endogenous inhibitory signals are overcome and platelets 
react rapidly to limit blood loss. The activating stimuli, such as collagen, vWF, ADP, TxA
2
 
and thrombin, which induce platelet adhesion, activation and aggregation ultimately regulate 
a central set of signalling mediators that support activation. Three principle mediator fami-
lies of platelet activation are phospholipase C (PLC), protein kinase C (PKC) and phosphati-
dylinositide-3-kinase (PI3K), and underlie two crucial events in platelet activation—secretion 
of amplifying mediators and activation of integrin αIIbβ3.
2.4. Platelet function beyond haemostasis
Platelets are recognised as pivotal players in numerous other processes ranging from inflam-
mation and atherosclerosis, fighting microbial infection and tumour growth and metastasis. 
Platelets are equipped to influence inflammation, the innate immune response and infection, 
by acting as sentinels in pathogen detection. They express a collection of pattern recogni-
tion receptors called toll-like receptors (TLRs) that identify molecular motifs called pathogen 
associated molecular patterns (PAMPs) and initiate immune responses [72]. Platelets express 
functional TLR 1–9, whilst TLR2 stimulation in platelets by bacteria through the activation of 
the PI3K signalling pathway induces a pro-inflammatory response [20]. Platelet TLR9 acti-
vation has been associated with thrombosis and oxidative stress, and is found within the 
T-granules in platelets [11].
Platelets interact with leukocytes, monocytes and granulocytes through different receptor-
ligand interactions (P-Selectin and PSGL-1 interaction) enabling intercellular communication 
[73]. The capacity of platelets to store and release copious inflammatory cytokines and che-
mokines is intimately associated to their role in inflammation. Platelets release microparticles 
linked to inflammatory pathways and which are associated with inflammatory diseases such 
as rheumatoid arthritis [74]. Platelets play key roles in infection and immune response to 
bacterial and viral infections. They are the first cell type to arrive at areas of vascular infection 
[75]. Thrombocytopenia (low platelet count) is a well-established manifestation of sepsis and 
studies suggests platelets play a functional role in the pathogenesis of sepsis and multi-organ 
failure [76].
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Platelets have significant roles in the pathogenesis of metastasis [77]. Tumour cells can aggre-
gate platelets in vitro and it has been proposed that platelet adhesion to metastatic cells can 
act as a ‘cloak’ around circulating tumour cells therefore acting as a shield for immune clear-
ance. This phenomenon of platelet cloaking has resulted in pro-survival, pro-angiogenic and 
epithelial mesenchymal transition (EMT) in cancer cells [78]. Platelets also release growth 
factors such as VEGF and PDGF that can expedite tumour growth [79]. Platelets are deeply 
implicated in wound healing and bone health, and indeed the use of platelet rich plasma 
(PRP) therapy (i.e. rich in growth factors and bioactive substances) is effective in osteoarthritis 
[10] and in muscle damage such as rotator cuff tendinopathy [80].
2.5. Assessing function: platelet function tests (PFT)
The different functions of platelets may be reliably detected with a wide spectrum of tests 
(Table 1). These can be utilised to identify inherited or acquired platelet dysfunction, monitor 
antiplatelet therapy, manage various aspects of platelet banking and transfusion, and to aid in 
the understanding of platelet physiology in basic research. PFTs are centred around principles 
of platelet function such as platelet adhesion and aggregation, platelet function under shear 
conditions, and measurement of the platelet releasate [81]. Platelet function testing began with 
the evaluation of the bleeding time (the time taken for platelets to occlude an in vivo wound), 
using the Duke procedure [82], before the development of light transmission aggregometry 
(LTA) revolutionised the study of platelet function. Considered the historical gold standard, 
LTA is a relatively easy technique that involves stirring a suspension of platelet rich plasma in 
a cuvette in the presence of a platelet agonist (such as ADP or collagen). The cuvette is placed 
between a light source and photocell. Agonist addition causes in vitro platelet aggregation 
and changes in light absorbance, which is detected by the photocell [83].
Investigation of platelet function in the environmental milieu of whole blood under conditions 
that take into account most of the physiological parameters that influence platelet adhesion 
and aggregation (red blood cells, white blood cells, plasma) is important. The PFA-100, The 
Impact-R Cone and Plate analyser and the global thrombosis test are examples of such assays. 
The PFA-100 assesses platelet aggregation under high shear where platelets are activated 
in whole blood by an amalgamation of high shear stress (5000–6000 s−1) and agonists (e.g. 
collagen and ADP), resulting in closure of an aperture [84]. The Impact-R Cone and Plate 
analyser is a point-of-care (POC) device which measures global platelet function by testing 
platelet adhesion and aggregation in whole blood, under arterial shear conditions [85, 86]. In 
this assay, platelet adhesion is dependent on plasma proteins vWF, fibrinogen and RBCs and 
WBCs. The addition of platelet agonists such as arachidonic acid (AA) and ADP in the system 
has enabled the evaluation of dual anti-platelet therapy [87–89]. The system is effective in 
the assessment of platelet function disorders in adults, [90] children [91] and new-borns [92].
2.6. Platelet indices
Platelet indices are useful as inexpensive non-invasive biomarkers for assessing platelet acti-
vation [93]. Platelet indices are straightforwardly measured by semi-automated counters in 
complete blood counts (CBC) and usually include four factors; platelet count (PLT), mean 
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platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), and depending 
on the analyser, platelet large cell ratio (PLCR). PLT is a universal indicator of haemosta-
sis in a clinical setting and is utilised as a sensitive biomarker for a range of diseases. High 
PLT, even within the physiological range of 150–450 μl, is associated with a greater risk of 
thrombosis and CVD suggesting that enhanced PLT encourage platelet hyperactivity and a 
pro-inflammatory state [94]. However, the consequence of high platelet numbers that are still 
within physiologic ranges remains unclear [95].
The indices MPV, PDW and PLCR are quantitative measures of the variability in platelet size. 
MPV reflects the average platelet size while PDW reflects the volume variability in platelet size 
Method Sample Principle
Platelet aggregation assays
Light transmission aggregometry 
(LTA)
Citrated PRP Measurement of light transmission in response to 
agonist-induced platelet activation
Impedance Aggregation Citrated WB Monitors changes in electrical impedance in relation 
to agonist-induced platelet aggregation. Whole blood 
specimen diluted 1:1 with physiologic saline, prior to 
testing 
VerifyNow Citrated WB Turbidimetric optical detection of platelet aggregation in 
whole blood in response to agonists/inhibitors
Plateletworks Citrated WB Platelet counting pre- and post-activation
Assays measuring release reactions
Lumi-aggregometry Citrated WB Combination of LTA/WBA with nucleotide release
Soluble platelet release markers 
(Txb2, PF4, BTF, scD40L)
Urine, serum, 
citrated plasma
Typically measured by ligand binding ELISA 
immunoassays
Shear-based assays
PFA-100/200 Citrated WB High-shear platelet adhesion and aggregation during 
formation of a platelet plug
Impact R cone and plate analyser Citrated WB Shear-induced platelet adhesion-aggregation upon 
specific surface
Global thrombosis test Native WB High-shear platelet plug formation—measurement of 
time cessation of WB flow
Platelet activation based assays
VASP phosphorylation Citrated WB Flow cytometry or ELISA measurement of VASP 
phosphorylation
Flow cytometry Citrated WB, PRP, 
washed platelets
Measurement of platelet glycoproteins, and activation 
markers; platelet leukocyte aggregates, platelet 
microvesicles
Typical platelet function tests range from assessment of their primary haemostatic function including measurement of 
granule secretion using lumi-aggregometry to whole blood shear based assays, which measure platelet function under 
flow conditions. Platelet function can be tested in washed platelets, whole blood or platelet rich plasma.
Table 1. Platelet function tests.
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[94, 96]. The volume of circulating platelets is heterogeneous with subsequent functional differ-
ences. Some authors suggest that larger platelets are metabolically more active than smaller plate-
lets, that they have faster rates of aggregation and release higher quantities of pro-thrombotic 
elements such as TxA
2
 and ADP [97]. MPV and PDW levels can be altered in several diseases 
including T2DM [98], CVD and atherosclerosis [93] (Berger et al., 2010), and in this regard they 
have been suggested as markers of subclinical platelet activation. PLCR and PCT may serve 
as sensitive biomarkers of platelet health [99]. PLCR indicates the percentage of large platelets 
present in blood [93]. PLCR is significantly higher in subjects with dyslipidaemia compared to 
healthy subjects [100] and higher in children with T2DM compared to healthy children. Moreover, 
Rechcinski et al., have hypothesised that PLCR has the potential to be a prognostic biomarker 
[101]. Importantly, thrombogenicity of large platelets may put individuals at higher risk of acute 
cardiovascular events. PCT is the volume of blood occupied by platelets as a percentage, similar 
to the erythrocyte measurement of haematocrit (HCT). PCT reflects total platelet mass and is 
calculated as PLT × MPV/107, providing comprehensive information about platelet activity. PCT 
has been proposed as a novel predictor of cardiovascular risk and higher PCT is associated with 
the risk of re-infarction and long-term mortality in CVD patients [102]. However, the clinical 
significance, reference values and efficacy of some of these parameters are still under exploration.
In peripheral blood, there is ample interplay between RBCs, WBCs and platelets [103] and 
altered levels of blood cells and their morphology have been associated with CVD [104]. Platelet 
adhesion and aggregate size, is influenced by platelet indices, RBC and WBC [86]. RBCs encour-
age platelets towards the vessel wall [105], which can affect platelet adhesion and aggregation. 
In this context, it is important to investigate the associations between the various indices of each 
blood cell to interpret the multicellular contribution to both thrombogenesis and CVD risk.
3. Conclusion
Novel techniques continue to emerge and develop the knowledge surrounding the platelet 
function regulation. The modern “omics” revolution enables simultaneous quantification of 
hundreds of molecules (e.g. protein or mRNA) from a single sample and their signatures may 
be reflective of platelet function changes. The amalgamation of transcriptomic and proteomic 
data and subsequent bioinformatic analysis will lead to a more complete characterisation of 
platelet function in response to environmental stimuli [106, 107]. Epigenetics and its ancil-
lary elements, including platelet secreted microvesicles (MVs), and microRNA (miRNA), and 
regulation of the platelet mitochondrial genome are new avenues of investigation and testing 
in platelet research [108–110].
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